[1]卓传尚,柳丽娟,周淑燕.AFP-L3和PIVKA-Ⅱ检测对高危人群良恶性肝病的鉴别诊断价值[J].现代检验医学杂志,2017,32(04):40-42,46.[doi:10.3969/j.issn.1671-7414.2017.04.011]
　ZHUO Chuan-shang,LIU Li-juan,ZHOU Shu-yan.Performance of Serum AFP-L3 and PIVKA-Ⅱ in Differential Diagnosis of Benign and Malignant Liver Disease in High Risk Population[J].Journal of Modern Laboratory Medicine,2017,32(04):40-42,46.[doi:10.3969/j.issn.1671-7414.2017.04.011]
点击复制

AFP-L3和PIVKA-Ⅱ检测对高危人群良恶性肝病的鉴别诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年04期
页码:
40-42,46
栏目:
论著
出版日期:
2017-07-25

文章信息/Info

Title:
Performance of Serum AFP-L3 and PIVKA-Ⅱ in Differential Diagnosis of Benign and Malignant Liver Disease in High Risk Population
文章编号:
1671-7414(2017)04-040-04
作者:
卓传尚; 柳丽娟; 周淑燕
福建医科大学孟超肝胆医院/福州市传染病医院检验科,福州 350025
Author(s):
ZHUO Chuan-shang; LIU Li-juan; ZHOU Shu-yan
Department of Clinical Laboratory, the Mengchao Hepatobiliary Hospital of Fujian Medical University,Fuzhou 350025,China
关键词:
原发性肝癌;  肝硬化;  慢性乙型肝炎;  异常凝血酶原;  甲胎蛋白异质体
分类号:
R735.7; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.04.011
文献标志码:
A
摘要:
目的 探讨AFP-L3和PIVKA-Ⅱ在联合检测对高危人群中良恶性肝病鉴别诊断的临床价值。方法 回顾性分析48例原发性肝癌、43例肝硬化和81例慢性乙型肝炎患者血清甲胎蛋白异质体(AFP-L3)和异常凝血酶原(PIVKA-Ⅱ)水平。结果 原发性肝癌组、肝硬化组和慢性乙型肝炎组三组间血清AFP水平差异无统计学意义(χ2=4.014,P=0.134); 原发性肝癌组AFP-L3和PIVKA-Ⅱ的中位值均高于肝硬化组和慢性乙型肝炎组(χ2=33.93,52.33,均P<0.001); AFP-L3诊断肝癌的特异度较高(92.74%),PIVKA-Ⅱ的敏感度较高(79.17%),二者以串联方式联合检测将准确度提高到84.88%。结论 AFP-L3和PIVKA-Ⅱ以串联方式联合检测有助于高危人群良恶性肝病的鉴别诊断。
Abstract:
Objective To explore the performance of serum AFP-L3 and PIVKA-Ⅱ in differential diagnosis of benign and malignant liver disease in high risk population.Methods The serum levels ofAFP-L3 and PIVKA-Ⅱin 48 patients with primary hepatic carcinoma,43 patientswith cirrhosis and 81 patients with chronic hepatitis B were analyzed retrospectively.Results There was no statistically different significance among the median levels of serum AFP in primary hepatic carcinoma patients,cirrhosis patients and chronic hepatitis B patients(χ2=4.014,P=0.134).Both median level of AFP-L3 and PIVKA-Ⅱ in primary hepatic carcinomapatients were higher than cirrhosis patients and chronic hepatitis B patients(χ2=33.93,52.33,both of P values were below 0.001).The specificity(92.74%)of AFP-L3 and the sensitivity(79.17%)of PIVKA-Ⅱ were all higher.The accuracy(84.88%)of combined detection in series was the highest,with its 47.92% ofsensitivity and 99.19% of specificity.Conclusion Combined detection PIVKA-Ⅱ and AFP-L3 series will help to differential diagnosis ofbenign and malignant liver disease in high risk population.

参考文献/References:

[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA:A Cancer J Clin,2016,66(2):115-132.
[2] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:themajor impact of China[J].Hepatology,2014,60(6):2099-2108.
[3] 刘田田,左维泽.慢性乙型肝炎患者血清中甲胎蛋白、糖链抗原19-9的临床意义分析[J].吉林医学,2014,35(8):1577-1579. Liu TT,Zuo WZ,.A analysis of the clinical significance of serum alpha-fetoprotein and carbohydrate antign-19-9 in chronic hapatitis B patients[J].Jilin Medical Journal,2014,35(8):1577-1579.
[4] Cheng J,Wang W,Zhang Y,et al.Prognostic role of pre-treatment serumAFP-L3% in hepatocellular carcinoma:systematic review and meta-analysis[J].PLoS One,2014,9(1):e87011.
[5] 周淑燕,卓传尚,柳丽娟,等.PIVKA-Ⅱ和AFP联合检测对原发性肝癌的诊断价值[J].现代检验医学杂志,2017,32(1):69-71. Zhou SY,Zhuo CS,Liu LJ,et al.Clinical value of serum PIVKA-Ⅱ and AFP detection for primary hepatocellular carcinoma[J].J Mod Lab Med,2017,32(1):69-71.
[6] Ji J,Wang H,Li Y,et al.Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellularcarcinoma in China:a large-scale,multicentre study[J].PLoS One,2016,11(4):e0153227.
[7] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946. Ministry of Health of the People's Repablic of China.Diagnosis,management and treatment of hepatoccllular carcinoma[V2001][J].Chinese Clinical Oncology,2011,16(10):929-946.
[8] 中华医学会肝病学分会和中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].胃肠病学,2016,21(4):219-240. Chinese Society of Hepatology Chinese Medical Association,Chinese Society of Infections Diseaseas Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A2015 update[J].Chin J Gastroenterol,2016,21(4):219-240.
[9] Lim TS,Kim DY,Han KH,et al.Combined use of AFP,PIVKA-II,and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma incirrhotic patients[J].Scand J Gastroenterol,2016,51(3):344-353.
[10] Park SJ,Jang JY,Jeong SW,et al.Usefulness of A-FP,AFP-L3,and PIVKA-II,and their combinations in diagnosing hepatocellular carcinoma[J].Medicine(Baltimore),2017,96(11):e5811.
[11] Choi JY,Jung SW,Kim HY,et al.Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP[J].World J Gastroenterol,2013,19(3):339-346.
[12] Kang KH,Kim JH,Kang SH,et al.The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma[J].Gut Liver,2015,9(2):224-230.

相似文献/References:

[1]李 峰,魏 群,周国雄,等.髓样细胞白血病-1基因 在原发性肝癌组织中的表达及临床意义[J].现代检验医学杂志,2016,31(03):69.[doi:10.3969/j.issn.1671-7414.2016.03.019]
　LI Feng,WEI Qun,ZHOU Guo-xiong,et al.Expression and Significance of Mcl-1 Gene in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(04):69.[doi:10.3969/j.issn.1671-7414.2016.03.019]
[2]薛顺和,袁东红,王 芳,等.肝硬化患者并发感染及死亡与肠道通透性实验检测的相关性研究[J].现代检验医学杂志,2017,32(01):95.[doi:10.3969/j.issn.1671-7414.2017.01.026]
　XUE Shun-he,YUAN Dong-hong,WANG Fang,et al.Correlation between Liver Cirrhosis Patients Combined with Infection or Death and Intestinal Permeability Test[J].Journal of Modern Laboratory Medicine,2017,32(04):95.[doi:10.3969/j.issn.1671-7414.2017.01.026]
[3]任雪维,张吉才.肝细胞肝癌患者血浆miR-29a水平的变化及其临床意义[J].现代检验医学杂志,2017,32(02):33.[doi:10.3969/j.issn.1671-7414.2017.02.009]
　REN Xue-wei,ZHANG Ji-cai.Changes of Plasma miR-29a Levels in Patients with Hepatocellular Carcinoma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(04):33.[doi:10.3969/j.issn.1671-7414.2017.02.009]
[4]许 娜a,刘永霞a,高莉莉a,等.肝硬化细菌感染患者血清中Presepsin检测的临床意义[J].现代检验医学杂志,2017,32(06):92.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　XU Naa,LIU Yong-xiaa,GAO Li-lia,et al.Clinical Value of Presepsin in the Diagnosis and Prognosis of Bacterial Infection in Cirrhosis[J].Journal of Modern Laboratory Medicine,2017,32(04):92.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[5]赵清侠,许丽荣,杨 莹,等.原发性肝癌患者血清VEGF浓度与抑郁症发生的相关性研究[J].现代检验医学杂志,2017,32(06):96.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHAO Qing-xia,XU Li-rong,YANG Ying,et al.Study on the Correlation between Serum VEGF Concentration and Major Depressive Disorder of Patients with Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2017,32(04):96.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]刘国振,陈秀余,张修欢.血清 miR-122-5p，miR-486-5p，AFP及 AFP-L3水平联合检测对原发性肝癌的诊断价值[J].现代检验医学杂志,2022,37(01):82.[doi:10.3969/j.issn.1671-7414.2022.01.017]
　LIU Guo-zhen,CHEN Xiu-yu,ZHANG Xiu-huan.Value of Combined Detection of Serum miR-122-5p, miR-486-5p, AFP and AFP-L3 Levels in the Diagnosis of Primary LiverCancer[J].Journal of Modern Laboratory Medicine,2022,37(04):82.[doi:10.3969/j.issn.1671-7414.2022.01.017]
[7]邢文静a,卢相琴,齐敬聪b,等.血清高尔基体糖蛋白73与MIF水平联合检测对原发性肝癌的诊断和预后价值研究[J].现代检验医学杂志,2022,37(02):66.[doi:10.3969/j.issn.1671-7414.2022.02.014]
　XING Wen-jinga,LU Xiang-qin,QI Jing-congb,et al.Study on the Diagnostic and Prognostic Value of Serum Golgiglycoprotein 73 Combined with MIF Level in Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2022,37(04):66.[doi:10.3969/j.issn.1671-7414.2022.02.014]
[8]齐 锐,王何斌,李 劲,等.原发性肝癌患者血清miR-196b 和miR-520f 表达水平及其临床诊断价值分析[J].现代检验医学杂志,2023,38(05):47.[doi:10.3969/j.issn.1671-7414.2023.05.009]
　QI Rui,WANG Hebin,LI Jing,et al.Expression and Clinical Diagnostic Value of Serum miR-196b and miR-520f in Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(04):47.[doi:10.3969/j.issn.1671-7414.2023.05.009]

备注/Memo

备注/Memo:
基金项目:福建中医药大学临床专项校管课题(XB2015071),福州市卫生计生科技计划项目(2016-S-wt9)。 作者简介:卓传尚(1974-),男,硕士学位,副主任技师,从事感染性疾病实验诊断与研究,E-mail:hjjzoe@163.com。
更新日期/Last Update: 1900-01-01